MRK - What's Going On With C4 Therapeutics Stock? | Benzinga
C4 Therapeutics, Inc. (NASDAQ: CCCC) shares are trading higher Friday, and the stock has gained more than 350% over the past five days. Here's a look at what's going on:
What To Know:
C4 Therapeutics announced data from the CFT7455 Phase 1 trial in relapsed/refractory multiple myeloma and an exclusive license and collaboration agreement with Merck & Co Inc (NYSE: